Sermorelin vs Ipamorelin: Which Is Better for Fat Loss?
Should I start on sermorelin or ipamorelin?
Start on sermorelin. Ipamorelin scores higher overall, yet sermorelin wins thirteen of the sixteen shared use cases and it is the one an anti-aging clinic actually prescribes. Ipamorelin is far cheaper and comes from the gray market. Both need a full twelve weeks before you judge either one.
- Ipamorelin scores 6.2 and sermorelin 5.9, but the overall gap is driven by cost and side-effect drag, not by results. On use cases, sermorelin leads 13 of 16.
- They are not the same class. Sermorelin agonises the pituitary GHRH receptor. Ipamorelin agonises the ghrelin receptor, GHS-R1a. Different doors into the same pulse.
- Sermorelin is a compounded prescription through a telehealth provider or clinic. Ipamorelin has no approved product and arrives through research-chemical channels.
- Cost runs the other way: an estimated $129 to $250 a month for sermorelin against $25 to $60 for ipamorelin.
- Sermorelin is the only one of the two with a real human efficacy trial behind it, in growth-hormone-deficient children, per Thorner 1996. Ipamorelin's one completed human efficacy trial failed, per Beck 2014.
- The dominant clinic protocol is not either one alone. It is a GHRH peptide plus a GHRP, which is exactly what these two are.
At a Glance
Sermorelin (GHRH 1-29)
- Efficacy 3.2
- Breadth 3.2
- Evidence 3.8
- Speed 3.0
- Durability 2.0
- Bioindividuality 3.3
- Safety Risk 1.8
- Side Effects 1.9
- Cost 2.8
- Effort 3.2
- Opportunity Cost 2.8
- Dependency 2.8
- Reversibility 1.8
- Body Composition
- Recovery Repair
- Sleep Quality
- Geriatric
GHRH 1-29 analogue, formerly approved as Geref, now compounded only. BioHarmony 5.9, worth trying.
Ipamorelin
- Efficacy 3.3
- Breadth 3.3
- Evidence 3.3
- Speed 3.2
- Durability 2.4
- Bioindividuality 3.3
- Safety Risk 1.8
- Side Effects 1.6
- Cost 2.6
- Effort 3.0
- Opportunity Cost 2.2
- Dependency 2.6
- Reversibility 1.6
- Sleep Quality
- Recovery Repair
- Bone Joint
- Injury Recovery
Selective ghrelin-receptor agonist with no approved indication. BioHarmony 6.2, worth trying.
Head-to-Head Verdict
| Use Case | Winner | Rationale |
|---|---|---|
| Body Composition | Sermorelin (GHRH 1-29) | Sermorelin 4.2 against ipamorelin's 2.0, the widest gap here, and still a modest score. A stabilized GHRH 1-29 analogue at 10 mcg/kg nightly for 16 weeks raised lean body mass in older men, per Khorram 1997, but not in women. A 6-week single 2 mg dose found nothing, per Vittone 1997. No human ipamorelin trial reports fat or lean-mass change. |
| Recovery Repair | Sermorelin (GHRH 1-29) | Sermorelin 4.0 against 2.4, on physiology rather than a recovery trial. GHRH 1-29 raised 24-hour growth hormone and IGF-1 in older men toward young-adult levels, per Corpas 1992, the mechanism behind faster repair. Ipamorelin's support is rodent: about 20 percent less glucocorticoid-induced hepatic nitrogen wasting, per Aagaard 2009. |
| Sleep Quality | Tie | Sermorelin 4.0 against 2.8, and neither number rests on a real sleep trial. The one sermorelin aging sleep experiment primed 2 elderly men over 12 days and sleep quality went down, per Murck 1997. Ipamorelin's evidence is a receptor proxy: ghrelin raised slow-wave sleep in 7 men, per Weikel 2003. The most marketed claim on both sides, the least supported. |
| Geriatric | Sermorelin (GHRH 1-29) | Sermorelin 2.6 against 1.8. Older adults with a lower baseline respond more, and GHRH 1-29 restored age-blunted growth hormone and IGF-1 toward young-adult levels in that exact group, per Corpas 1992. Ipamorelin has no human aging data. Whether raising growth hormone helps net aging outcomes is still contested for both. |
| Skin Beauty | Sermorelin (GHRH 1-29) | Sermorelin 2.5 against 1.6, on one measurement inside a study designed for something else. Skin thickness rose in both sexes over 16 weeks, per Khorram 1997. That is a single secondary finding, not a cosmetic trial. Ipamorelin's skin and collagen claims are anecdotal at months 3 to 6 with no controlled human data behind them. |
| Bone Joint | Ipamorelin | The only row ipamorelin wins: 2.2 against 1.8. It raised bone mineral content in adult female rats comparably to growth hormone, by expanding bone size rather than density, per Svensson 2000, and counteracted glucocorticoid-driven loss of bone formation, per Andersen 2001. Sermorelin has no bone endpoint. Rodent bone is not a human joint result. |
| Muscle Growth | Tie | Sermorelin 2.3 against 1.9, with no human hypertrophy endpoint either side. The pulse either produces is far smaller than injected growth hormone, and against recombinant GH in children, GHRH 1-29 came out weaker, per Chen 1993. Ipamorelin's animal work shows anti-catabolic protection under steroid stress, not growth. Neither builds mass. |
| Metabolic Health | Tie | Sermorelin 1.8 against 1.6, and this row is a monitoring item rather than a benefit. Growth hormone opposes insulin. In children on GHRH 1-29, fasting glucose and insulin rose over 12 months, per Kirk 1994. Ipamorelin has no human metabolic data in either direction. Track fasting glucose on whichever one you start. |
| Longevity | Tie | Sermorelin 2.2 against 1.7, and both numbers describe an absence. No lifespan or healthspan data exists for either peptide, and the class literature is divided on whether raising growth hormone in older adults helps or harms, per Sigalos and Pastuszak 2018. Nobody should start either one for longevity. |
Cost Comparison
| Intervention | Monthly Cost | Notes |
|---|---|---|
| Sermorelin | $129 to $250 | ESTIMATE, priced 2026-09-08, telehealth channel, at 100 mcg. Sermorelin exists only as a compounded preparation. Telehealth programs advertise $129 to $149 a month on multi-month plans and clinic-bundled programs run $175 to $250, which is the accessible legitimate band.That price buys a prescriber, a compounding pharmacy and a paper trail. It is a channel estimate, not a measured price you are guaranteed to pay, and grey-market vials undercut it by moving the risk onto product quality. |
| Ipamorelin | $25 to $60 | ESTIMATE, priced 2026-09-07, research-chemical channel, at 100 to 150 mcg. A 5 mg vial at $25 to $50 gives 33 to 50 doses, about 1.1 to 1.7 months, so roughly $18 to $45 a month plus $8 to $13 of bacteriostatic water, syringes and swabs. The report cites $40 to $90 for compounded material.Nothing in that figure pays for oversight. There is no approved product, so a third-party HPLC and mass-spec certificate is the minimum bar and it is on you to demand one. |
| The difference | About $100 to $200 a month | Sermorelin costs roughly four to five times what ipamorelin costs, and almost all of that gap is the channel rather than the molecule. One is a compounded prescription, the other is a research chemical you reconstitute yourself.Both figures are estimates. If price is what decides your first order, understand what the cheaper number leaves out: no prescriber, no compounding pharmacy, and purity you have to verify yourself. |
When to Switch
Both run on the same clock. The assessment window is 12 weeks on each, full effect lands at 12 weeks on each, and the only difference in early feel is that ipamorelin is first noticeable at about 1 week against sermorelin's 2. That single week is not a reason to pick anything.
Judge at 12 weeks, on consistent fasted pre-sleep dosing, with IGF-1 and fasting glucose measured before you start and again at the end.
Move from sermorelin to ipamorelin when the monthly cost is the thing stopping you from staying consistent, or when you have a bone or joint reason and are willing to act on rodent data.
Move from ipamorelin to sermorelin when you want a prescriber and a compounding pharmacy in the loop, when nothing moved on a full 12-week ipamorelin block, or when your goal is body composition, where sermorelin's subrating is 4.2 against 2.0.
These two can also run together, and that is the honest third answer. A GHRH peptide plus a ghrelin-receptor secretagogue hits two complementary pathways for a larger combined pulse than either alone, and sermorelin plus a GHRP such as ipamorelin is the dominant clinic pattern, typically 100 to 300 mcg sermorelin with the GHRP for 8 to 12 weeks per cycle.
The synergy is mechanistically grounded, not proven for this exact pair in a human outcome trial. Run one alone first, for one full window, so you know which half is doing anything.
Who Should Pick What?
First peptide ever, going through a clinic or telehealth provider
Sermorelin (GHRH 1-29)
This is the case the whole page is about. Sermorelin is the one a clinic actually starts you on: a compounded prescription, one 100 mcg injection nightly for 8 to 12 weeks, with a prescriber attached. It is also the only one of the two with a former FDA approval and a real human efficacy trial, per Thorner 1996.
Body composition is the reason you are doing this at all
Sermorelin (GHRH 1-29)
Subrating 4.2 against 2.0. The positive adult signal is a 16-week study in older men, per Khorram 1997, and even that came with no lean-mass gain in women and a null 6-week counterpart, per Vittone 1997. Ipamorelin has no human body-composition data at all, so there is nothing to weigh on its side of this question.
Price decides whether you stay consistent for 12 weeks
Ipamorelin
An estimated $25 to $60 a month against $129 to $250. A protocol you can actually afford to run for a full window beats one you abandon at week 5. The trade is real though: no prescriber, no compounding pharmacy, and a third-party certificate of analysis you have to insist on yourself.
You want the version with the least paperwork and the fewest side effects
Ipamorelin
Ipamorelin is the cleaner molecule on paper. It is the first selective growth-hormone secretagogue, with no significant ACTH or cortisol rise, per Raun 1998, and it scores better than sermorelin on side-effect burden. Understand what you are buying with that: selectivity, not proven results.
Older adult with documented low IGF-1
Sermorelin (GHRH 1-29)
Geriatric subrating 2.6 against 1.8, and the reason is specific. GHRH 1-29 at 0.5 to 1 mg twice daily for 14 days moved age-blunted growth hormone and IGF-1 back toward young-adult levels in older men, per Corpas 1992. That is the single strongest adult datapoint in this comparison and it belongs to sermorelin.
Expecting proven fat loss, better sleep, or faster healing
Tie
Neither, yet. The most-marketed benefit on each side is the worst supported on each side. Sermorelin's only aging sleep experiment made sleep worse in 2 elderly men, per Murck 1997, and ipamorelin's single completed human efficacy trial missed its endpoint at p=0.15, per Beck 2014. Fix training, protein and sleep timing before you inject anything.
You compete in a tested sport
Tie
Neither. Growth-hormone-releasing factors and growth-hormone secretagogues are both prohibited at all times under WADA category S2, sermorelin by name. There is no dose, timing or washout answer here that makes this workable while you are subject to testing.
Active or hormone-sensitive cancer, pregnancy, or uncontrolled diabetes
Tie
Neither, and the cancer case is absolute rather than cautionary, since growth-hormone and IGF-1 signaling can drive proliferation. Pregnancy and breastfeeding have no safety data on either. Uncontrolled diabetes rules out both, because growth hormone opposes insulin and fasting glucose can rise, per Kirk 1994.
Research Highlights
-
Mechanism Difference
These are two different doors into the same room. Sermorelin agonises the pituitary GHRH receptor, amplifying your own episodic growth-hormone pulses while leaving somatostatin feedback intact, which raises IGF-1 without replacing the axis.Ipamorelin agonises the ghrelin receptor, GHS-R1a, and is selective enough that it does not meaningfully raise ACTH, cortisol or prolactin, per Raun 1998. The two mechanisms are complementary rather than redundant, which is why a GHRH peptide plus a GHRP is the standard clinic stack.
-
Safety Comparison
Neither peptide separates itself on safety risk, and both score the same on it. The contraindication lists overlap almost completely: active or hormone-sensitive cancer, pregnancy, breastfeeding, uncontrolled diabetes, critical illness, and tested sport under WADA category S2.The differences are narrow. Sermorelin adds active proliferative diabetic retinopathy and hypersensitivity to GHRH analogues; ipamorelin adds congestive heart failure and, explicitly, any vial with no third-party certificate of analysis. Ipamorelin scores slightly better on side-effect burden, which is the selectivity showing up in the numbers.
-
Cost Comparison
Sermorelin runs an estimated $129 to $250 a month at 100 mcg through telehealth and clinic programs, priced 2026-09-08. Ipamorelin runs an estimated $25 to $60 a month at 100 to 150 mcg through the research-chemical channel, priced 2026-09-07. Both figures are estimates, not measured retail prices.That four to five times gap is almost entirely the channel, not the molecule. Sermorelin's price includes a prescriber and a compounding pharmacy. Ipamorelin's does not include either, which is why a third-party certificate of analysis is the minimum bar on that side.
-
Editorial Verdict
Ipamorelin scores 6.2 and sermorelin 5.9, and that 0.3 points the wrong way for a first protocol. The overall gap comes from cost and side-effect burden, where ipamorelin wins outright. On the 16 shared use cases, sermorelin scores higher on 13, ties 2, and loses only bone and joint.So start on sermorelin: a compounded prescription, 100 mcg nightly, fasted, pre-sleep, for 8 to 12 weeks, with IGF-1 and fasting glucose measured at both ends. It is also the only one of the two with a real human efficacy trial, per Thorner 1996. Add or switch to ipamorelin once you know what sermorelin alone does for you.
-
Durability
Neither peptide leaves anything behind. Both score low on durability and low on reversibility, which is the same fact stated twice: benefits stop when dosing stops. The pediatric GHRH 1-29 data makes it explicit, with the height-velocity effect reversing off-drug, per Kirk 1994.Plan on a repeating 8 to 12 week cycle rather than a one-off course, and decide in advance what result would justify running the next one. If nothing moved in a full 12-week window, stop without ceremony.
Frequently Asked Questions
- Which one should I start with, sermorelin or ipamorelin?
- Sermorelin, if you are going through a clinic or telehealth provider. It is the one with a prescriber attached, a former FDA approval, and a real human efficacy trial behind it, per Thorner 1996. It also scores higher on 13 of the 16 shared use cases. Start at 100 mcg nightly, fasted, pre-sleep, for 8 to 12 weeks, and judge it at 12 weeks.
- Why does ipamorelin score higher overall if sermorelin wins most use cases?
- Because the overall score prices in the downsides, not just the results. Ipamorelin is cheaper, has a slightly lighter side-effect profile thanks to its selectivity, and carries less opportunity cost. Sermorelin scores better on efficacy evidence. So 6.2 against 5.9 is a verdict on the whole package, while the use-case rows are a verdict on what each one does.
- What is the actual difference between a GHRH analogue and a GHRP?
- Different receptors. Sermorelin is a GHRH analogue: it hits the pituitary GHRH receptor and amplifies your own growth-hormone pulses while leaving somatostatin feedback intact. Ipamorelin is a ghrelin-receptor secretagogue: it hits GHS-R1a, a separate pathway into the same pulse. That is why the two are complementary rather than interchangeable.
- Can I run sermorelin and ipamorelin together?
- Yes, and it is the dominant clinic pattern rather than an exotic stack. A GHRH peptide plus a GHRP hits two complementary pathways for a larger combined pulse than either alone, typically 100 to 300 mcg sermorelin with a GHRP such as ipamorelin for 8 to 12 weeks.The synergy is mechanistically grounded and clinic-standard, not proven for this exact pair in a human outcome trial. Run one alone first so you know which half is working.
- How long before I know if it is working?
- Twelve weeks on either one. Ipamorelin is first noticeable at about 1 week and sermorelin at about 2, but that early feel is mostly sleep and appetite noise. Full effect lands at 12 weeks on both, and the assessment window is 12 weeks on both.Measure IGF-1 and fasting glucose before you start and again at the end, then decide.
- Which one is cheaper?
- Ipamorelin, by a lot. An estimated $25 to $60 a month against sermorelin's $129 to $250. Both are estimates rather than measured retail prices.The gap is the channel, not the peptide. Sermorelin's price includes a prescriber and a compounding pharmacy. Ipamorelin has no approved product at any price, so the cheaper number leaves out the oversight and hands you the job of verifying purity with a third-party certificate of analysis.
- Will either one actually help me sleep?
- Nobody has shown that in a decent trial. Sleep is the most popular reason people run both, and the direct evidence is thin to negative. The one sermorelin-specific aging sleep experiment primed 2 elderly men for 12 days and sleep quality decreased, per Murck 1997.Ipamorelin's case rests on a proxy, where ghrelin infusion raised slow-wave sleep in 7 men, per Weikel 2003. Anecdotes are consistent; controlled data is not there.
- Who should not take either one?
- Anyone with active or hormone-sensitive cancer, which is an absolute contraindication because growth-hormone and IGF-1 signaling can drive proliferation. Anyone pregnant or breastfeeding, with no safety data. Anyone with uncontrolled diabetes, since fasting glucose can rise, per Kirk 1994. Anyone in a critical illness.Sermorelin adds active proliferative diabetic retinopathy. Ipamorelin adds congestive heart failure. Both are prohibited at all times in tested sport under WADA category S2, and neither should be bought from a vendor who cannot produce a third-party certificate of analysis.
Evidence Sources
- RCT Growth hormone-releasing hormone 1-29 in growth-hormone-deficient children (Thorner 1996) (1996) GHRH 1-29 at 30 mcg/kg nightly raised height velocity from 4.1 to 8.0 cm/yr at 6 months in 110 prepubertal children, with 74 percent good responders. The pivotal trial behind the Geref approval.
- RCT GHRH 1-29 versus growth hormone in hypothalamic growth-hormone deficiency (Chen 1993) (1993) Randomized 6-month trial in 60 children. GHRH height velocity of 9.2 to 9.3 cm/yr against 14.6 for growth hormone, with GH significantly superior.
- Trial GHRH 1-29 in idiopathic short stature over 12 months (Kirk 1994) (1994) Height velocity rose from 4.8 to 7.2 cm/yr in 18 children. Fasting glucose and insulin rose, and the effect reversed off-drug.
- RCT GHRH 1-29 reverses age-related growth hormone and IGF-1 decline in older men (Corpas 1992) (1992) 0.5 to 1 mg twice daily for 14 days moved growth hormone and IGF-1 toward young-adult levels. The strongest adult datapoint that the somatotroph axis stays responsive with age.
- RCT Stabilized GHRH 1-29 analog for 16 weeks in older adults (Khorram 1997) (1997) 10 mcg/kg nightly raised lean body mass, well-being and skin thickness in older men. No lean-mass gain in women.
- Trial GHRH 1-29 at 2 mg nightly for 6 weeks in older men (Vittone 1997) (1997) No change in body composition and no IGF-1 rise in 11 men. Single nightly dosing judged less effective than divided dosing.
- Trial GHRH priming and sleep-endocrine activity in elderly men (Murck 1997) (1997) 12 days of priming in 2 elderly men did not restore sleep-endocrine efficiency and sleep quality decreased. A negative result on the most-marketed sermorelin benefit.
- Preclinical Ipamorelin, the first selective growth hormone secretagogue (Raun 1998) (1998) Defining selectivity characterization: growth-hormone release with no significant ACTH or cortisol rise, which is the entire case for ipamorelin over GHRP-2 and GHRP-6.
- RCT Ipamorelin for postoperative ileus, phase 2 randomized trial (Beck 2014) (2014) n=114, failed its primary endpoint at p=0.15, and development was discontinued. The only completed human efficacy trial of ipamorelin for anything.
- Preclinical Ipamorelin and bone mineral content in adult female rats (Svensson 2000) (2000) Ipamorelin and GHRP-6 raised bone mineral content comparably to growth hormone, by expanding bone size rather than density. No human bone endpoint exists.
- Preclinical Ipamorelin counteracts glucocorticoid-induced loss of bone formation in rats (Andersen 2001) (2001) Anti-catabolic bone effect under steroid stress in adult rats. Animal data, no human equivalent.
- Preclinical Ipamorelin and glucocorticoid-induced hepatic nitrogen wasting in rats (Aagaard 2009) (2009) About 20 percent less nitrogen wasting. The closest thing to recovery evidence ipamorelin has, and it is a rodent nitrogen-balance result.
- Trial Ghrelin infusion and slow-wave sleep in healthy men (Weikel 2003) (2003) Ghrelin raised slow-wave sleep in 7 men. A GHS-R1a receptor proxy for ipamorelin's sleep claim, not a study of ipamorelin.
- Review Growth hormone secretagogue safety and efficacy review (Sigalos and Pastuszak 2018) (2018) Class-level review of secretagogue safety and efficacy, calling for long-term safety data including cancer endpoints. Ipamorelin sits inside this parent class.
- Review Growth hormone secretagogues and body composition in hypogonadal males (Sinha 2020) (2020) Body-composition context for the parent secretagogue class, where the best data belongs to compounds other than ipamorelin. Mouse data showed early weight gain and unchanged total fat.
- Regulatory WADA 2026 Prohibited List, category S2 (2026) Growth-hormone-releasing factors including sermorelin are prohibited at all times under S2.2.4, and growth-hormone secretagogues including ipamorelin are prohibited at all times under S2.
Glossary
Quick reference for the medical and technical terms used in this comparison.
- GHRH Growth Hormone-Releasing Hormone
- The hypothalamic hormone that tells the pituitary to release growth hormone. Sermorelin is a synthetic fragment of it, the first 29 amino acids.
- GHRP Growth Hormone-Releasing Peptide
- A peptide that triggers growth-hormone release through the ghrelin receptor rather than the GHRH receptor. Ipamorelin is one, which is why the two stack.
- GHS-R1a Growth Hormone Secretagogue Receptor 1a
- The ghrelin receptor. Ipamorelin's target, and a completely separate door into growth-hormone release from sermorelin's.
- GHRHR Growth Hormone-Releasing Hormone Receptor
- The pituitary receptor sermorelin agonises. Hitting it amplifies your own pulses instead of replacing the axis, which is why somatostatin feedback stays intact.
- IGF-1 Insulin-Like Growth Factor 1
- The downstream hormone that carries most of growth hormone's effects. The blood marker to track on either peptide, before starting and at 12 weeks.
- GRF(1-29) Growth Hormone-Releasing Factor, amino acids 1 to 29
- The other way sermorelin is written on labels and in papers, along with sermorelin acetate and the discontinued brand name Geref.
- S2 WADA Prohibited List category S2
- Peptide hormones, growth factors and mimetics. Both peptides fall here and are banned at all times in tested sport, not only in competition.
- COA Certificate of Analysis
- Third-party HPLC and mass-spec proof of what is in a vial. Required on both sides, and a vial without one is a listed contraindication on the ipamorelin report.
- SWS Slow-Wave Sleep
- The deepest non-REM sleep stage, where the natural overnight growth-hormone pulse happens. The endpoint in the ghrelin infusion study, per Weikel 2003.
